An Open-Label, Multi-Center, Single-Arm, Phase 1 Study Evaluating the Safety and Pharmacokinetics of Dinutuximab Beta as Maintenance Therapy in Chinese Patients With High-Risk Neuroblastoma
Latest Information Update: 20 Oct 2024
At a glance
- Drugs Dinutuximab beta (Primary) ; Isotretinoin
- Indications Neuroblastoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors BeiGene
- 29 Jan 2024 Status changed from active, no longer recruiting to completed.
- 02 Dec 2022 Status changed from recruiting to active, no longer recruiting.
- 16 Jun 2022 Status changed from not yet recruiting to recruiting.